BRIEF-Agios Provides Update On Phase 2B Trial Of Tebapivat In Lower-Risk Myelodysplastic Syndromes

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

AGIO

0.00

May 29 (Reuters) - Agios Pharmaceuticals Inc AGIO.O:

  • AGIOS PROVIDES UPDATE ON PHASE 2B TRIAL OF TEBAPIVAT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

  • AGIOS PHARMACEUTICALS - WILL NOT ADVANCE TEBAPIVAT IN LOWER-RISK MYELODYSPLASTIC SYNDROMES

  • AGIOS PHARMACEUTICALS - PHASE 2B TRIAL RESULTS FOR TEBAPIVAT IN LR-MDS DID NOT MEET PREDEFINED THRESHOLD

  • AGIOS PHARMACEUTICALS - TEBAPIVAT WELL TOLERATED WITH NO NEW SAFETY SIGNALS IDENTIFIED

  • AGIOS PHARMACEUTICALS - TEBAPIVAT PHASE 2 TRIAL IN SICKLE CELL DISEASE TOPLINE DATA EXPECTED SECOND HALF 2026

Source text: ID:nGNX3DPktn

Further company coverage: AGIO.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.